RT Journal Article
SR Electronic
T1 Multi-task deep learning-based survival analysis on the prognosis of late AMD using the longitudinal data in AREDS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.26.21262548
DO 10.1101/2021.08.26.21262548
A1 Gregory Ghahramani
A1 Matthew Brendel
A1 Mingquan Lin
A1 Qingyu Chen
A1 Tiarnan Keenan
A1 Kun Chen
A1 Emily Chew
A1 Zhiyong Lu
A1 Yifan Peng
A1 Fei Wang
YR 2021
UL http://medrxiv.org/content/early/2021/09/03/2021.08.26.21262548.abstract
AB Age-related macular degeneration (AMD) is the leading cause of vision loss. Some patients experience vision loss over a delayed timeframe, others at a rapid pace. Physicians analyze time-of-visit fundus photographs to predict patient risk of developing late-AMD, the most severe form of AMD. Our study hypothesizes that 1) incorporating historical data improves predictive strength of developing late-AMD and 2) state-of-the-art deep-learning techniques extract more predictive image features than clinicians do. We incorporate longitudinal data from the Age-Related Eye Disease Studies and deep-learning extracted image features in survival settings to predict development of late-AMD. To extract image features, we used multi-task learning frameworks to train convolutional neural networks. Our findings show 1) incorporating longitudinal data improves prediction of late-AMD for clinical standard features, but only the current visit is informative when using complex features and 2) “deep-features” are more informative than clinician derived features. We make codes publicly available at https://github.com/bionlplab/AMD_prognosis_amia2021.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported by the intramural program funds and contracts from the National Center for Biotechnology Information/National Library of Medicine/National Institutes of Health, the National Eye Institute/National Institutes of Health, Department of Health and Human Services (Contract HHS-N-260-2005-00007-C; ADB contract NO1-EY-5-0007; Grant No K99LM013001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is proved by the NIH Data Access Committee (Project ID: 25378).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000001.v3.p1 https://github.com/bionlplab/AMD_prognosis_amia2021